Table 5.
Baseline characteristics of patients of our cohort and the two clinical trials
| This analysis | CHAARTED trial | STAMPEDE trial | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Patients included | 159 | 397 | 272 |
| Age | |||
| Median | 71 | 64 | 65 |
| Range | 49–85 | 36–88 | – |
| IQR | 66–76 | – | 62–70 |
| Performance score | |||
| 0 | 69 (43.4) | 277 (69.8) | 204 (75) |
| 1–2 | 55 (34.6) | 120 (30.2) | 68 (25) |
| Unknown | 35 (22) | 0 | 0 |
| Volume of metastasis | |||
| Low | 73 (45.9) | 134 (33.8) | 124 (45.6) |
| High | 86 (54.1) | 263 (66.2) | 148 (54.4) |
| Gleason sum score | |||
| ≤7 | 54 (34) | 117 (29.5) | 51 (18.8) |
| 8–10 | 104 (64.8) | 241 (60.7) | 188 (69.1) |
| Unknown | 2 (1.3) | 39 (9.8) | 33 (12.1) |
| Baseline PSA levels | |||
| Median | 129 | 50.9 | 96.8 |
| Range | 0.19–9584 | 0.2–8540.1 | – |
| IQR | 25–425 | – | 37.8–348.1 |
| Prior treatment | |||
| No | 137 (86.2) | 289 (72.8) | 261 (96) |
| Yes | 22 (13.8) | 108 (27.2) | 11 (4) |
CHAARTED = Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer; IQR = interquartile range; PSA = prostate-specific antigen; STAMPEDE = Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy.